台股 » 個股 » 國光生 » 籌碼相關 » 券商分點績效

國光生

(4142)
可現股當沖
  • 股價
    27.90
  • 漲跌
    ▼0.30
  • 漲幅
    -1.06%
  • 成交量
    701
  • 產業
    上市 生技醫療類股
  • 633人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
國光生 (4142)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/03/26     後一日»

券商獲利排行 - 2024/03/26

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  4.92%31.4031.42424026.626.6027.9
  4.64%29.6-0.129.72324126.626.626.627.9
  4.79%25.5025.52020026.626.6027.9
  4.77%16.5016.51313026.626.6027.9
  4.89%14.3014.31111026.626.6027.9
  4.83%14.1014.11111026.626.6027.9
  5.08%13.5013.51010026.626.6027.9
  4.89%130131010026.626.6027.9
  4.89%130131010026.626.6027.9
  4.89%130131010026.626.6027.9
  4.69%12.5012.51010026.726.7027.9
  5.00%11.9011.989026.626.626.727.9
  4.69%8.808.877026.626.6027.9
  4.82%7.707.766026.626.6027.9
  5.08%6.706.755026.626.6027.9
  5.08%6.706.755026.626.6027.9
  5.08%6.706.755026.626.6027.9
  5.08%6.706.755026.626.6027.9
  3.55%6.606.657226.626.626.627.9
  4.92%6.506.555026.626.6027.9
  4.89%6.506.555026.626.6027.9
  3.31%5.30.3546226.726.726.827.9
  4.59%4.904.944026.726.7027.9
  4.49%4.804.844026.726.7027.9
  5.08%40433026.626.6027.9
  5.08%40433026.626.6027.9
  5.08%40433026.626.6027.9
  4.89%3.903.933026.626.6027.9
  4.82%3.803.833026.626.6027.9
  4.76%3.803.833026.626.6027.9
  4.69%3.703.733026.726.7027.9
  4.69%3.703.733026.726.7027.9
  4.69%3.703.733026.726.7027.9
  4.10%3.303.333026.826.8027.9
  4.10%3.303.333026.826.8027.9
  2.81%30.42.624226.726.626.827.9
  2.59%2.80.22.514226.726.626.727.9
  5.08%2.702.722026.626.6027.9
  5.08%2.702.722026.626.6027.9
  5.08%2.702.722026.626.6027.9
  5.08%2.702.722026.626.6027.9
  5.08%2.702.722026.626.6027.9
  5.08%2.702.722026.626.6027.9
  5.08%2.702.722026.626.6027.9
  4.99%2.602.622026.626.6027.9
  4.89%2.602.622026.626.6027.9
  4.89%2.602.622026.626.6027.9
  4.89%2.602.622026.626.6027.9
  4.89%2.602.622026.626.6027.9
  4.89%2.602.622026.626.6027.9

券商虧損排行 - 2024/03/26

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -4.89%-74.10-74.1-5705726.6026.627.9
  -4.82%-55.10-55.1-4304326.6026.627.9
  -4.42%-51.8-0.7-51.1-4044426.626.826.627.9
  -4.95%-30.20-30.2-2302326.6026.627.9
  -4.89%-260-26-1902026.626.726.627.9
  -4.51%-24.10-24.1-2002026.7026.727.9
  -3.56%-9.40-9.4-731026.626.626.627.9
  -4.45%-9.40-9.4-71826.626.626.627.9
  -4.19%-7.80-7.8-61726.626.726.627.9
  -5.08%-6.70-6.7-50526.6026.627.9
  -5.08%-6.70-6.7-50526.6026.627.9
  -4.16%-6.6-0.1-6.5-51626.626.726.627.9
  -4.89%-6.50-6.5-50526.6026.627.9
  -4.69%-6.20-6.2-50526.7026.727.9
  -1.23%-6.21.1-7.3-6131926.626.626.727.9
  -5.08%-5.40-5.4-40426.6026.627.9
  -5.08%-5.40-5.4-40426.6026.627.9
  -4.79%-5.10-5.1-40426.6026.627.9
  -4.49%-4.80-4.8-40426.7026.727.9
  -3.20%-4.2-0.2-4-22526.626.626.627.9
  -5.28%-4.20-4.2-30326.5026.527.9
  -5.08%-40-4-20326.626.926.627.9
  -4.95%-3.90-3.9-30326.6026.627.9
  -4.82%-3.80-3.8-30326.6026.627.9
  -4.69%-3.70-3.7-30326.7026.727.9
  -3.38%-3.60.1-3.7-31426.726.626.727.9
  -2.22%-3.50.2-3.8-33626.626.626.627.9
  -5.08%-2.70-2.7-20226.6026.627.9
  -5.08%-2.70-2.7-20226.6026.627.9
  -5.08%-2.70-2.7-20226.6026.627.9
  -5.08%-2.70-2.7-20226.6026.627.9
  -4.89%-2.60-2.6-20226.6026.627.9
  -4.89%-2.60-2.6-20226.6026.627.9
  -3.13%-2.50-2.5-11326.726.726.727.9
  -4.69%-2.50-2.5-10226.726.726.727.9
  -4.69%-2.50-2.5-20226.7026.727.9
  -4.69%-2.50-2.5-20226.7026.727.9
  -2.31%-2.50.1-2.5-12426.626.626.627.9
  -4.30%-2.30-2.3-20226.8026.827.9
  -4.10%-2.20-2.2-20226.8026.827.9
  -2.81%-1.5-0.2-1.3-11226.726.826.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
  -5.08%-1.30-1.300126.626.726.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
  -5.08%-1.30-1.3-10126.6026.627.9
國光生去年營運轉虧 今年拚重回成長軌道Anue鉅亨-2024/03/13
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
國光生 相關文章